Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 5/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1484126 | 1.00 | ALDH1A1 (0.65) | ALDH1A1CYP2C19POLBTDP1APEX1 | |
| SCHEMBL15529385 | 1.00 | ALDH1A1 (0.65) | ALDH1A1CYP2C19POLBTDP1APEX1 | |
| SCHEMBL2033299 | 1.00 | ALDH1A1 (0.65) | ALDH1A1CYP2C19POLBTDP1APEX1 | |
| SCHEMBL7232865 | 1.00 | ALDH1A1 (0.65) | ALDH1A1CYP2C19POLBTDP1APEX1 | |
| Hydrochloric Acid SCHEMBL26613189 | 0.98 | ALDH1A1 (0.63) | ALDH1A1CYP2C19POLBTDP1APEX1 | |
| Hydrochloric Acid SCHEMBL26613207 | 0.98 | ALDH1A1 (0.63) | ALDH1A1CYP2C19POLBTDP1APEX1 | |
| Hydrochloric Acid SCHEMBL19668549 | 0.98 | ALDH1A1 (0.63) | ALDH1A1CYP2C19POLBTDP1APEX1 | |
| Hydrochloric Acid SCHEMBL19668550 | 0.98 | ALDH1A1 (0.63) | ALDH1A1CYP2C19POLBTDP1APEX1 | |
| SCHEMBL24062391 | 0.83 | POLB (0.70) | ALDH1A1POLBTDP1APEX1SMN1; SMN2 | |
| SCHEMBL20346210 | 0.83 | POLB (0.70) | ALDH1A1POLBTDP1APEX1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117720452-A | Preparation method of 3-aza-tricyclo [4.2.1.0 (2.5) ] nonane-7-ene-4-one | 成都科圣原医药科技有限公司 | 2024-03-19 | — | — | CN | claimed |
| US-12534514-B2 | Biological and synthetic molecules inhibiting respiratory syncytial virus infection | Fraunhofer-Gesellschaft Zur Forderung Der Angewanditen Forschung (DE) | 2026-01-27 | — | — | US | disclosed |
| CN-120202243-A | Thermosetting resin composition, cured film, substrate, and electronic component | 捷恩智株式会社 | 2025-06-24 | — | — | CN | disclosed |
| CN-119731211-A | Cross-linked multispecific antibodies | 恩拉扎治疗公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119136842-A | Cyclodextrin complexes that specialize in resolution mediators | 西蒂斯制药有限责任公司 | 2024-12-13 | — | — | CN | disclosed |
| WO-2024150597-A1 | THERMOSETTING RESIN COMPOSITION, CURED FILM, SUBSTRATE, AND ELECTRONIC COMPONENT | JNC株式会社 | 2024-07-18 | — | — | WO | disclosed |
| WO-2024130161-A2 | NOVEL CAMPTOTHECIN DERIVATIVES AND CONJUGATES THEREOF | BIONECURE THERAPEUTICS INC (US) | 2024-06-20 | — | — | WO | disclosed |
| CN-117720452-A | Preparation method of 3-aza-tricyclo [4.2.1.0 (2.5) ] nonane-7-ene-4-one | 成都科圣原医药科技有限公司 | 2024-03-19 | — | — | CN | disclosed |
| CN-111902394-B | Compositions and methods relating to salts of specific pro-inflammatory regressive mediators | 西蒂斯制药有限责任公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20240034753-A1 | THERAPEUTIC PEPTIDES | COHBAR, INC. | 2024-02-01 | — | — | US | disclosed |
| EP-1516876-A1 | Mediators of hedgehog signalling pathways, compositions and uses related thereto | Curis, Inc. (US) | 2005-03-23 | — | — | EP | disclosed |
| EP-1216234-B1 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO | CURIS INC (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20030232846-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-12-18 | — | — | US | disclosed |
| US-6545005-B1 | Quinazolone derivatives | CURTIS, INC. | 2003-04-08 | — | — | US | disclosed |
| WO-2001019800-A9 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO | CURIS INC (US) | 2002-10-03 | — | — | WO | disclosed |
| EP-1244626-A2 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2002-10-02 | — | — | EP | disclosed |
| EP-1216234-A2 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO | Curis, Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001042216-A2 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-06-14 | — | — | WO | disclosed |
| WO-2001019800-A2 | MEDIATORS OF HEDGEHOG SIGNALING PATHWAYS, COMPOSITIONS AND USES RELATED THERETO | CURIS, INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| EP-0557519-B1 | PROCESS FOR PREPARING SULFONAMIDE DERIVATIVE OF NORBORNANE | SHIONOGI & CO (JP) | 1997-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534514-B2 | Biological and synthetic molecules inhibiting respiratory syncytial virus infection | VIP, LNPEP, SARS1 | ALDH1A1 4847/4885CYP2C19 4608/4885POLB 2124/4885 |
| US-20030232846-A1 | Caspase inhibitors and uses thereof | CASP1, CASP3, CASP2 | ALDH1A1 2618/4885CYP2C19 1368/4885POLB 4042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.